Presentation ACC 2024 ApoA-I Event ReducinG in Ischemic Syndromes II (AEGIS-II) Trial Presenter: C. Michael Gibson April 06, 2024 REGISTER for free or LOG IN to view this content Coronary CAD Pharma ACC 2024 Up Next Presentation ACC 2024 Principal Results from the RELIEVE-HF Trial Presenter: Gregg W. Stone April 06, 2024 More slides + Presentation ACC 2024 Acoramidis May Improve Cardiac Function and Promote Regression in Transthyretin Amyloid Cardiomyopathy: Data From the ATTRibute-CM Cardiac Magnetic Resonance Substudy Presenter: Yousuf Razvi April 06, 2024 Presentation ACC 2024 Bridge-TIMI 73a: Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk Presenter: Brian Bergmark April 07, 2024 We Recommend
Presentation ACC 2024 Principal Results from the RELIEVE-HF Trial Presenter: Gregg W. Stone April 06, 2024
Presentation ACC 2024 Acoramidis May Improve Cardiac Function and Promote Regression in Transthyretin Amyloid Cardiomyopathy: Data From the ATTRibute-CM Cardiac Magnetic Resonance Substudy Presenter: Yousuf Razvi April 06, 2024
Presentation ACC 2024 Bridge-TIMI 73a: Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk Presenter: Brian Bergmark April 07, 2024